Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.

Anticipatory nausea in animal models: a review of potential novel therapeutic treatments. Exp Brain Res (2014) 0.78

Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program. Oncologist (2016) 0.77

Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. Med Sci Monit (2017) 0.75

Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol (2003) 3.88

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer (2004) 3.04

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol (2005) 2.86

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer (2003) 2.78

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The Italian Group for Antiemetic Research. N Engl J Med (2000) 2.70

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer (2009) 2.32

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1994) 1.69

Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer (2011) 1.52

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer (2005) 1.37

5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs (1998) 1.37

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer (2003) 1.30

A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer (2007) 1.27

Chemotherapy-induced nausea and vomiting. Cancer J (2008) 1.25

Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol (2006) 1.22

A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting. Jpn J Clin Oncol (2009) 1.16

Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded study. Korean J Anesthesiol (2013) 1.13

Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol (2007) 1.06

Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol (2007) 0.97

Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol (1998) 0.94

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology (1992) 0.91

Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol (2001) 0.83

Antiemetic effects of YM060, a potent and selective serotonin (5HT)3-receptor antagonist, in ferrets and dogs. Jpn J Pharmacol (1991) 0.82

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer (1999) 0.79

[Nasea injection in the prophylaxis of gastrointestinal reaction induced by chemotherapeutic agents]. Zhonghua Zhong Liu Za Zhi (2000) 0.77

Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther (2004) 0.76

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol (2012) 3.49

Dogs cloned from adult somatic cells. Nature (2005) 3.24

Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10

Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res (2008) 2.42

A genetic link between cold responses and flowering time through FVE in Arabidopsis thaliana. Nat Genet (2004) 2.25

Is shoulder pain for three months or longer correlated with depression, anxiety, and sleep disturbance? J Shoulder Elbow Surg (2012) 2.14

Gold nanorod-photosensitizer complex for near-infrared fluorescence imaging and photodynamic/photothermal therapy in vivo. ACS Nano (2011) 1.65

Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res (2009) 1.61

Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem (2010) 1.58

Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol (2012) 1.49

Single-port-access laparoscopic-assisted vaginal hysterectomy versus conventional laparoscopic-assisted vaginal hysterectomy: a comparison of perioperative outcomes. Surg Endosc (2010) 1.46

Clinical characteristics of adnexal masses in Korean children and adolescents: retrospective analysis of 409 cases. J Minim Invasive Gynecol (2010) 1.45

Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (2011) 1.42

Single port access laparoscopic adnexal surgery. J Minim Invasive Gynecol (2009) 1.40

Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res (2012) 1.36

Quality of life and sexual problems in disease-free survivors of cervical cancer compared with the general population. Cancer (2007) 1.33

Single-port access laparoscopic-assisted vaginal hysterectomy: a novel method with a wound retractor and a glove. J Minim Invasive Gynecol (2009) 1.32

Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther (2009) 1.30

Benign metastasizing leiomyoma with multiple lymph node metastasis: a case report. Cancer Res Treat (2011) 1.29

Adenoid cystic carcinoma of the Bartholin's gland: report of two cases and review of the literature. Gynecol Oncol (2005) 1.25

Embryonic natural orifice transumbilical endoscopic surgery (E-NOTES) for adnexal tumors. Surg Endosc (2009) 1.22

Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol (2011) 1.22

Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum (2011) 1.21

Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. J Comp Neurol (2004) 1.21

Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS (2003) 1.21

The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol Oncol (2010) 1.20

Single port access laparoscopic adnexal surgery versus conventional laparoscopic adnexal surgery: a comparison of peri-operative outcomes. Eur J Obstet Gynecol Reprod Biol (2010) 1.19

Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Lett (2007) 1.15

Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol (2011) 1.15

Light signalling mediated by phytochrome plays an important role in cold-induced gene expression through the C-repeat/dehydration responsive element (C/DRE) in Arabidopsis thaliana. Plant J (2002) 1.14

Theoretical study of the ligand-CYP2B4 complexes: effect of structure on binding free energies and heme spin state. Proteins (2004) 1.13

Arthroscopic management of septic arthritis of the shoulder joint. J Bone Joint Surg Am (2006) 1.11

Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia. Gynecol Oncol (2005) 1.10

Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer. J Mol Cell Biol (2012) 1.10

Genome-wide expression profiling of ARABIDOPSIS RESPONSE REGULATOR 7(ARR7) overexpression in cytokinin response. Mol Genet Genomics (2006) 1.09

AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med (2011) 1.08

Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res (2011) 1.08

Determination of substrate specificity and putative substrates of Chk2 kinase. Biochem Biophys Res Commun (2003) 1.07

Single-port access subtotal hysterectomy with transcervical morcellation: a pilot study. J Minim Invasive Gynecol (2009) 1.07

NADPH oxidase mediates depressive behavior induced by chronic stress in mice. J Neurosci (2012) 1.07

The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol (2009) 1.06

Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol (2010) 1.04

Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma. Gynecol Oncol (2007) 1.03

The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results. Gynecol Oncol (2009) 1.03